

camurus®

Company presentation

November 2025



Forward looking statements

This presentation contains forward-looking statements that provide our expectations or forecasts of future events such as new product developments and regulatory approvals and financial performance.

Camurus is providing the following cautionary statement. Such forward-looking statements are subject to risks, uncertainties and inaccurate assumptions. This may cause actual results to differ materially from expectations and it may cause any or all of our forward-looking statements here or in other publications to be wrong. Factors that may affect future results include currency exchange rate fluctuations, delay or failure of development projects, loss or expiry of patents, production problems, unexpected contract, patent, breaches or terminations, government-mandated or market-driven price decreases, introduction of competing products, Camurus' ability to successfully market products, exposure to product liability claims and other lawsuits, changes in reimbursement rules and governmental laws and interpretation thereof, and unexpected cost increases.

Camurus undertakes no obligation to update forward-looking statements.

Camurus snapshot



Rapidly growing commercial stage company

Leader in opioid dependence treatment with Buvidal® and Brixadi® weekly and monthly depots



Advancing late-stage pipeline with blockbuster potential

Prospect for multiple new approvals in endocrinology and rare disease indications



Unique FluidCrystal® technology platform

Commercially validated with a broad range of applications



Strong operational and financial performance

Sustainable profitability since 2022

Listed on
Nasdaq Stockholm
Ticker **CAMX**;
Employees: **275+**

Significant recent progress

Commercial execution



- Global leadership in long-acting treatment of opioid dependence
- Double-digit Buvidal sales growth in Europe, Australia and MENA
- Best-in-class US launch of Brixadi
- Establishment of own commercial infrastructure in the US
- Ocyesa® in acromegaly launched in Germany

Advancing R&D pipeline



- Ocyesa approved in the EU and UK for the treatment of acromegaly
- Positive results from POSITANO Phase 2b study main part
- SORENTA Phase 3 study advancing in GEP-NET
- Positive results from Phase 1b study of once-monthly semaglutide


Corporate development



- Solid financial performance with high profitability
- Meaningful investment in R&D
- Strong cash position
~ SEK 3.5 billion – no debt
- License agreement with Lilly for FluidCrystal® long-acting incretins


Strong financial development

Revenues



■ One-time revenue related to Brixadi US approval
 ■ Revenues excl. one-times for Brixadi US approval

Profit before tax



■ One-time revenue related to Brixadi US approval
 ■ Profit before tax excl. Brixadi US approval revenue

Full year 2025 guidance

*Revenue**

SEK 2.3 – 2.6 billion
 + 23 – 39% vs. 2024


Profit before tax

SEK 0.9 – 1.2 billion
 + 63 – 117% vs. 2024


* Revised 6 November 2025

FluidCrystal[®] extended-release technology

- ✓ Easy and convenient administration
- ✓ Rapid onset & long-acting release
- ✓ Controlled by composition, liquid crystal phase structure and biodegradation
- ✓ Applicable across substance classes
- ✓ Compatible with prefilled syringes, autoinjector pens, and other advanced devices
- ✓ Manufacturing by standard processes



Broad and diversified product portfolio and pipeline



Other clinical stage programs include CAM2032 (prostate cancer), CAM2043 (PAH⁴), and CAM2047 (CINV⁵)

Opioid dependence – an escalating global health crisis

Largest society burden of all drugs¹


- 60 million opioid users worldwide¹
- Escalating US opioid overdose deaths²

High need for better access to care and new treatment alternatives

Significant limitation with current daily medications

- Burdens and stigma of daily medications, limited treatment compliance, medication diversion, misuse and unintended pediatric exposure

High US overdose death rate



¹United Nations: World drug report 2024; ²www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm



Buvidal – game changing opioid dependence treatment

Weekly and monthly, subcutaneous buprenorphine for individualized treatment of opioid dependence within a framework of medical, social and psychological treatment in adults and adolescents 16 years or over¹

“Buvidal became my way out”

Justin, Buvidal patient in Australia

¹ SmPC Buvidal

Buvidal has demonstrated significant benefits to patients and society

- ✓ Superior treatment outcome and patient satisfaction¹⁻⁴
- ✓ Blocks subjective opioid effects from first dose²
- ✓ Reduces treatment burden and improve quality of life^{4,5}
- ✓ Decrease risk of diversion, misuse and pediatric exposure^{6,7}
- ✓ Provides cost savings⁸

¹Lofwall et al. *JAMA Int. Med.* 2018;178(6): 764-773; ²Walsh et al, *JAMA Psychiatry* 2017;74(9):894-902; ³Frost, M., et al. *Addiction.* 2019;114(8):1416-1426. doi: 10.1111/add.14636; ⁴Lintzeris, N., et al. *JAMA Network Open.* 2021;4(5):e219041. doi:10.1001/jamanetworkopen.2021.9041; ⁵Barnett et al *Drug and Alcohol Dependence* 2021; <https://doi.org/10.1016/j.drugalcdep.2021.108959>; ⁶EPAR for Buvidal; ⁷Dunlop, A. J., et al. *Addiction.* 2021. <https://doi.org/10.1111/add.15627>; ⁸Dunlop, A. Oral presentation at CPDD June 2020.



Global leadership in long-acting opioid dependence treatment

Wide and growing access to Buvidal and Brixadi



- Available across four continents

Strong growth of Buvidal in Europe and Australia

- Double-digit growth for six consecutive years
- Estimated 67,000 in treatment with Buvidal in Europe and Australia end of September 2025
- Target more than 100,000 patients on Buvidal in 2027

Increasing Brixadi market share in the US

- Camurus' licensee Braeburn launched in Sep 2023
- Strongest launch ever in therapy area
- Brixadi est. peak market potential > USD 1 bn¹



Growing scientific evidence base

Strong scientific support for Buvidal/Brixadi

– More than 240 scientific publications

Selected recent and planned scientific conference participation in 2025/26

	Q3/Q4 2025			Q1/Q2 2026		
International	CPDD 14-18 Jun New Orleans, US	IMiA 29-31 Aug Sydney, AUS	ATHS 21-24 Oct Biarritz, FR	ASAM 23-26 April San Diego, US	EUROPAD 29-31 May Bucharest, Romania	ALBATROS 9-11 June Paris, France
National (selected)	Fed. Addiction 22-23 May Angers, FR	Suchtmedizin 3-5 July Munich, DE	Suchtsymp. Oct Grundlsee, AT	APSAD 9-12 Nov Sydney, AUS	RCGP January UK	APP 26 March AUS
	SEPD 4-7 Jun Madrid, ES	Prison Congr. Oct Montpellier, FR	RCPsych AC&E 9-10 Oct Wales, UK	Addiktum Nov/Dec Helsinki, Fi		JKSG March Zurich, Switzerland

Recent key publications¹⁻³

Substance Abuse and Rehabilitation

Dovepress
Taylor & Francis Group

Open Access Full Text Article

ORIGINAL RESEARCH

Patient Satisfaction and Resource Utilization Following Introduction of Long-Acting Injectable Buprenorphine (LAIB) in Scottish Prisons

Craig Sayers¹, Daniel Mogford²

¹Prison Healthcare, NHS Forth Valley, Stirling, Scotland, UK; ²Camurus Ltd., Duxford, Cambridge, UK

Correspondence: Craig Sayers, Prison Healthcare NHS Forth Valley, National Prison Care Network, c/o HMP Glenochil Health Centre, HMP Glenochil, King O'Muir Road, Tullibody, Clackmannanshire, FK10 3AD, UK. Tel +44 1259 767309, Email craig.sayers@nhs.scot

RESEARCH

Open Access

Reduced need for inpatient care following introduction of long-acting injectable buprenorphine

Emelie Gauffin^{1,2}, Antonio Marques Franca², Elena Pizzaro Ferrero², Zeb Freij¹, Isa Pihllyck², Mikael Sandell^{1,5}, Charlotte Gedeon⁶, He Zhang⁷, David Andersson⁸, Gustav Tinghög^{8,9} and Andrea Johansson Capusan^{1,10}

Drug and Alcohol Dependence Reports 15 (2022) 100328



Contents lists available at ScienceDirect

Drug and Alcohol Dependence Reports

journal homepage: www.elsevier.com/locate/dadr

Long acting injectable buprenorphine: Perspectives from service-users, staff and stakeholders^{2*}

Rebecca Fish^{1,2}, Céu Mateus^{1,2}, Hannah Maiden³, Euan Lawson^{1,2}, Mark Limmer⁴

¹ Division of Health Research, Loughborough University, UK

² Loughborough Medical School, Loughborough University, UK



Octreotide SC depot, CAM2029

CAM2029 is a long-acting octreotide in development for three serious rare disease indications

- ✓ Acromegaly
- ✓ Gastroenteropancreatic neuroendocrine tumors (GEP-NET)
- ✓ Polycystic liver disease (PLD)

Designed for enhanced efficacy and patient convenience vs. current somatostatin receptor ligands (SRLs)

CAM2029 designed to address key limitations of current first-generation SRLs


- ✓ Ready-to-use FluidCrystal® technology
- ✓ Rapid onset and long-acting octreotide release¹
- ✓ 5-fold octreotide bioavailability vs Sandostatin LAR with potential for improved efficacy¹⁻³
- ✓ State-of-the-art, pre-filled autoinjector pen enabling convenient patient self-administration
- ✓ Subcutaneous administration with thin needle (22-gauge, 12.5mm)
- ✓ Room temperature storage




CAM2029 provides high SRL exposure

~5x higher octreotide plasma exposure for CAM2029 vs. Sandostatin LAR

- CAM2029 octreotide plasma levels in the range of immediate release octreotide



Comprehensive CAM2029 clinical program



A patient-centric acromegaly treatment

Acromegaly is a rare, slowly progressive, chronic and serious condition typically caused by a tumor of the pituitary gland and overproduction of growth hormone. This results in excess growth of bones and tissue and a range of other symptoms and, if untreated, to premature death.




Positive results from ACROINNOVA 1 – CAM2029 provided robust biochemical control

ACROINNOVA 1 study design

- 24-week, randomized, double blind, placebo-controlled Phase 3 study

Patient population


- Biochemically controlled on first-generation SRL*



Superiority achieved

- 77.2% vs. 37.5% patients with $\text{IGF-1} \leq 1 \text{ ULN}$ with CAM2029 versus placebo, $p=0,00018$

IGF-1 levels well controlled



CAM2029 improved

- Treatment convenience
- Acromegaly quality of life
- Patient satisfaction

CAM2029 was well tolerated

- Safety profile comparable to well established profile for first generation SRLs
- Most AEs were mild or moderate and transient injection site reactions and gastrointestinal side-effects
- No serious reactions related to CAM2029


Positive topline results from ACROINNOVA 2

ACROINNOVA 2 study design


- 52-week, open-label safety study with further extension

Patient population

- New patients; uncontrolled or controlled with IGF-1 < 2xULN
- Patients who completed ACROINNOVA 1



Improved acromegaly symptoms with CAM2029



ACROINNOVA 2 results



- Reinforcing long-term safety and effectiveness in ACROINNOVA 1
- Increased response rate from SoC baseline in new recruited patients
- Roll-over placebo patients from ACROINNOVA 1 regained IGF-1 control with CAM2029

Improved patient reported outcomes for CAM2029 vs standard-of-care baseline

- Treatment satisfaction
- Quality of life
- Injection experience

Positive ACROINNOVA 2 extension study data

Improved biochemical response for patients during treatment with CAM2029



TSQM – treatment satisfaction questionnaire for medication

* Transferred to standard-of-care (SoC) – either octreotide LAR or lanreotide Autogel – after completion of ACROINNOVA 2 main part. When ACROINNOVA extension study started, patients were reinvited to join study for another year on CAM2029. Time on SoC between 15 to 95 weeks (median 35 weeks)

Medical information and dissemination of ACROINNOVA results

Pre-launch activities

- Meeting with acromegaly stakeholders
- National and regional advisory board meeting
- Payer engagement and submissions
- Commercial and medical affairs readiness

Scientific conferences in 2025

Q1 2025	Q2 2025	Q3 2025	Q4 2025
ENETS 5-7 Mar <i>Krakow PL</i>	AACE 15-17 May <i>Orlando US</i>	IPS 9-11 Jul <i>San Francisco US</i>	NANETS 23-25 Oct <i>Austin US</i>
DGE 19-21 Mar <i>Baden-Baden DE</i>	ESPE/ESE 10-13 May <i>Copenhagen DK</i>	ENDO 12-15 Jul <i>San Francisco US</i>	ENEA 3-5 Dec <i>Marseille FR</i>
	ACRO	NET	

Rapid fire presentation, educational program and posters of ACROINNOVA results at ENDO¹



Oczyesa - the first monthly subcutaneous octreotide depot¹⁻³

Autoinjector pen



Oczyesa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.¹



5-fold bioavailability vs octreotide LAR with potential for improved efficacy^{1,2,5}



Convenient and easy self-administration to improve patients' treatment experience¹⁻³



Autoinjector pen with a hidden, thin (22-gauge) needle^{1,4}



Stored at room temperature and ready to use^{1,4}

LAR – Long-acting release

1. Oczyesa® Summary of Product Characteristics (SmPC), Camurus AB, Sweden. June 2025; 2. Tibergh F et al. Br J Clin Pharmacol 2015;80:460–72; 3. Pavel M et al. Cancer Chemother Pharmacol 2019;83:375–85; 4. Ferone D et al. J Clin Endocrinol Metab 2025;110:1729–39; 5. Glatard A et al. Clin Pharmacokinet. 2025;64(7):1079–1092.

Internal photographic material

Initiating the European launch of Oczyesa

Start in wave 1 countries

- Significant switch opportunity from SoC
 - Est. 3,000 – 5,000 acromegaly patients on first generation SRL treatments
 - Additional 500 – 800 newly diagnosed patients start treatment every year
 - Notably, current estimates indicate significantly higher numbers, representing a potential upside

Positive response from physicians and patients

- Appreciated product profile and clinical evidence
- High willingness to switch to Oczyesa
- Promising initial response from payers

Teams in place and ready to go

- ~10 sales representatives, 5 MSLs and 3 market access

Planning PMA submissions in wave 2

Oczyesa wave 1 countries



LAUNCHED IN GERMANY 1 NOVEMBER 2025


Oczyesa[®]
(octreotide)
prolonged-release
solution for injection



Individuals shown are AI generated models, not real patients

Considerable opportunity in Germany

~2,000 target patients in Germany¹⁻⁵



Market potential in Germany

– SRL acromegaly annual sales ~EUR 50 million⁶

German physician's positive to Oczykesa profile

"It will make it possible to treat acromegaly much more effectively and with fewer complications."

"It is a self-injection with a subcutaneous pen. Everyone knows this from the weight loss jabs. That's a blockbuster."

"Autoinjector – means that one can self-administer but without seeing the needle and that is unique."

"It's very positive. And very different from all the other treatments we have for acromegaly. Hopeful. Very, very good I would say."

High interest to switch to treatment with Oczykesa

– Physician indicate that initially 30 – 60% of patients are suitable for switching to Oczykesa



Potential to become new standard of care for GEP-NET

Neuroendocrine tumors are cancerous tumors originating from cells in the endocrine and nervous system. The tumors can occur throughout the body, most common they occur in the gastrointestinal tract and lungs. The disease can be chronic with serious symptoms and complications.




SORENTO assessing CAM2029 superiority in PFS vs SoC in patients with GEP-NET

Randomized, active-controlled Phase 3 study

- Randomized, multi-center, open-label, active-controlled Phase 3 study of CAM2029 vs. long-acting octreotide or lanreotide in patients with GEP-NET
- Fulfills regulatory requirements for safety and efficacy

Patient population

- Patients with confirmed, advanced and well-differentiated GEP-NET (grade 1 to grade 3).
- SORENTO has a majority Grade 2 NETs



Primary endpoint


- Superiority in progression free survival, PFS, vs. standard of care (first-line medical treatment), hazard ratio 0.65
- Assessed after 194 documented PFS events

Secondary endpoints include

- Overall survival
- PROs (e.g., treatment satisfaction, quality of life)
- Safety

Recruitment completed end 2023

- 332 patients enrolled across 12 countries, exceeded randomization target (302)





Positive results from POSITANO in polycystic liver disease

Polycystic liver disease is a rare, genetic, and chronic disorder characterized by progressive growth of cysts in the liver, which can cause severe symptoms and result in impaired quality of life for patients.




Polycystic liver disease

Disease characteristics and prevalence

- Progressive growth of liver cysts of various sizes
- Estimated 37,000 target patients with symptomatic polycystic liver disease (PLD) in US, EU4 and UK¹
- No available pharmacological treatment for PLD

Treatment options

- Somatostatin receptor ligands show promise in clinical studies: decreasing liver volume, symptoms, and improving quality of life in symptomatic patients PLD²⁻⁴
- CAM2029 has orphan drug designation for ADPLD in EU and the US and ongoing applications for PLD associated with AKPKD



POSITANO – Phase 2b study in PLD

Trial design

- 53-week randomized, placebo-controlled, three-arm study
- Open label extension for 120 weeks

Key eligibility criteria

- Symptomatic PLD (isolated or associated with ADPKD)
- htTLV $\geq 1800\text{ml/m}$ at screening

Primary endpoint


- Liver volume change from baseline to week 53 compared to placebo

Key secondary endpoint

- Camurus' developed PRO, PLD-S

Secondary endpoints


- Total liver cyst volume
- Total kidney volume in ADPKD patients
- PLD symptoms and quality of life
- Safety
- PK and immunogenicity




POSITANO met the primary endpoint

Reduction in height adjusted total liver volume change with CAM2029 vs baseline

Main and sensitivity analyses for the primary endpoint Week 53




Treatment difference between CAM2029 groups and placebo




CAM2029 reduces liver cyst volume vs placebo

Total liver cyst volume change from baseline



Difference CAM2029 vs placebo



POSITANO topline results summary for CAM2029

Efficacy conclusions

- **Reduction of liver volume growth vs placebo**
 - Primary endpoint supported by sensitivity analyses
- **Reduction of total liver cyst volume growth vs placebo**
- **Kidney volume reduction indicated in patients with PLD associated with ADPKD**
- **Improved PLD symptoms**
 - Reduction of PLD-S score versus baseline
 - Improved symptoms indicated in several additional PROs (PLD-Q, PGI-S, CGI-S)
- **Robust decrease of IGF-1 vs placebo**

Safety profile

- **Treatment generally well tolerated**
- **Safety profile consistent with that of other injectable SRLs**
- **No new or unexpected safety issues were identified**
- **High study and treatment retention**
- **All eligible patients entered the extension phase**

CAM2029 recent milestones and expected progress ahead

AcroInnova™

Pivotal randomized placebo controlled and long-term safety trials in acromegaly

- ✓ ACROINNOVA Phase 3 program completed
- ✓ **EC market approval in June 2025**
- ✓ **MHRA UK approval in August 2025**
- ✓ **Oczyesa first launch in Germany in November 2025**
- **NDA resubmission with potential new PDUFA H1 2026**

SORENTO™

Subcutaneous Octreotide Randomized Efficacy in Neuroendocrine Tumors

- ✓ SORENTO Phase 3 start Q4 2021
- ✓ SORENTO fully enrolled Q4 2023
- **Target number PFS events exp. mid to late 2026**

positano™

Polycystic liver Safety and efficacy Trial with subcutaneous Octreotide

- ✓ Orphan drug designation for PLD in EU and US
- ✓ Positive POSITANO study results in June 2025
- ✓ **Orphan designation for ADPKD in the US and EU**
- **End-of-phase 2 meeting with FDA early 2026**

Significant sales potential for CAM2029 across indications

CAM2029 peak sales estimates >2 billion USD across indications¹⁻³

	TERRITORY	PATIENT POPULATION	EST. PEAK PATIENT SHARE	EST. PEAK SALES
ACRO ¹	EU/AUS	16,500 ⁴	20 – 35%	€30 – 65 million
	US	10,000	25 – 40%	\$150 – 280 million
NET ¹	EU/AUS	68,000 ⁴	30%	€300 – 400 million
	US	37,000	40%	\$1,200 – 1,500 million
PLD ¹	EU/AUS	15-18,000 ⁴	30 – 40%	€80 – 100 million
	US	12-13,000	30 – 40%	\$200 – 300 million

¹ Globe Life Science 2020-22, data on file;

² Assuming €10-12.5k (EU/AUS) and \$60-70K (US) per year net pricing in acromegaly, €15-20k (EU/AUS) and \$80-100K (US) per year net pricing in NET, and €17.5k (EU/AUS) and \$60K (US) per year net pricing in PLD

³ Patient numbers extrapolated from EU4+UK estimates by assuming same prevalence across European countries and Australia





Early-stage programs

Several early-stage programs advancing


- ✓ Completed treatment in Phase 1b study of monthly semaglutide (CAM2056)
 - ✓ Positive topline results announced
- ✓ Partnership with Eli Lilly for long-acting incretins progressing

Phase 1b study of once-monthly semaglutide

Randomized Phase 1b study comparing CAM2056 with once-weekly semaglutide (Wegovy®)

– Assessing pharmacokinetics, pharmacodynamics and safety in 80 participants with overweight or obesity

Study design



Positive top-line results from Phase 1b study of CAM2056


Similar or greater reduction of body weight, A1c and fasting glucose

- ✓ CAM2056 produced dose-dependent PD response
 - Weight change from baseline to Day 85 was -9.3% for CAM2056 10 mg versus -5.2% for weekly semaglutide per label; treatment difference -4.1% (-7.1%, -1.1%), $p=0.008$
 - Mean A1c change from baseline to Day 85 for CAM2056 10 mg was -0.44%; treatment difference vs weekly semaglutide -0.32% (-0.50%, -0.14%), $p<0.001$
- ✓ Comparable C_{max} at four times the dose of weekly semaglutide (Wegovy®)
 - Prolonged time to C_{max} and extended release, consistent with monthly dosing

CAM2056 was well tolerable with a consistent safety profile

- ✓ Similar safety and tolerability to weekly semaglutide dosed according to label
 - No new or unexpected safety events
 - The most common adverse events were mild to moderate and transient GI events
 - Limited number of injection site reactions; all mild and transient
- ✓ Dose escalation was well tolerated up to highest initiation in group 5, which showed a tendency for more GI events
- ✓ Few discontinuations; 1-2 per CAM2056 group* vs 2 for weekly semaglutide

Weight reduction from baseline



Next steps – CAM2056

Phase 2b study planned in 2026, including

- Dose initiation and escalation schedule established in Phase 1b study
- Extended treatment exposure to establish long term safety

Parallel preparations for Phase 3

- Progress final product presentation
- Authority discussions

Potential indications

- Type 2 diabetes
- Weight management
- Inflammation
- Neuropsychiatric disorders
- Substance use disorders

License agreement with Lilly on long-acting incretins

Partnership focused on long-acting therapies based on FluidCrystal and Lilly's proprietary drug compounds

- Lilly obtained license to research, develop, manufacture and commercialize long-acting incretin products based on FluidCrystal
- Includes up to four Lilly proprietary drug compounds within the exclusivity scope:
 - Dual GIP and GLP-1 receptor agonists
 - Triple GIP, glucagon and GLP-1 receptor agonists
 - An option to include amylin receptor agonists

Camurus eligible to receive:

- Up to \$290 million in license fees, development and regulatory milestone payments
- Up to \$580 million in sales-based milestone payments
- Tiered mid-single digit royalties on global net product sales



Camurus progressing towards Vision 2027

- Diversifying the business through commercial expansion and pipeline advances
- Adding inorganic growth through business development

5x

Five-fold revenue growth
(to SEK 4.5 billion)



Establishment of US
commercial infrastructure

4

Approvals for four R&D
pipeline programs

~50%

Operating margin
around 50 percent



Significant near-term opportunities

- Continued Buvidal growth in Europe and RoW
- Increasing Brixadi penetration in the US
- Ocyesa launch execution in Europe (first wave markets)
- US marketing approval of Oclaiz in acromegaly
- Clinical results for CAM2029 in GEP-NET
- Diversification through business development



Camurus AB | Rydbergs torg 4, SE-224 84 Lund, Sweden
P +46 46 286 57 30 | info@camurus.com | camurus.com

Shareholders and analyst coverage

Shareholders as of 31 October 2025	Number of shares	% of capital	% of votes
Sandberg Development AB	18,280,692	30.8	30.8
Fourth Swedish National Pension Fund	2,808,776	4.7	4.7
Swedbank Robur Fonder	2,325,048	3.9	3.9
Fredrik Tiberg, CEO	1,500,000	2.5	2.5
Vanguard	1,468,233	2.5	2.5
Handelsbanken fonder	1,359,759	2.3	2.3
Avanza Pension	1,238,601	2.1	2.1
Capital Group	1,228,245	2.1	2.1
SEB Funds	973,224	1.6	1.6
AFA Försäkring	906,812	1.5	1.5
Carnegie Fonder	834,652	1.4	1.4
BlackRock	755,206	1.3	1.3
Norges bank	742,052	1.3	1.3
Länsförsäkringar Fonder	658,140	1.1	1.1
Third Swedish National Pension Fund	633,163	1.1	1.1
Other shareholders	24,136,031	39.8	39.8
In total	59,848,634	100.0	100.0

Analysts

DNB Carnegie

Erik Hultgård

Handelsbanken

Suzanna Queckbörner

Jefferies

Shan Hama

Nordea

Viktor Sundberg

Pareto

Dan Akschuti

Stifel

Oscar Haffen Lamm

SEB

Christopher Uhde

ABG Sundal Collier

Georg Tigalov-Bjerke

Kempen

Romy O'Connor

Redeye*

Richard Ramanus

Experienced and committed management team



Fredrik Tiberg, PhD
President & CEO, CSO
In Company since 2002
Holdings: 1,500,000 shares, 42,000 employee options and 13,500 PSP units

Education: M.Sc. in Chem. Eng., Lund Institute of Technology, PhD and Assoc. Prof. Physical Chemistry, Lund University.
Previous experience: More than 20 years executive leadership experience from the pharmaceutical industry. Prof Physical Chemistry, Lund University; Visiting Prof at Oxford University; Section Head, Inst. for Surface Chemistry.



Anders Vadsholt
Chief Financial Officer
In Company since: 2025
Holdings: 2,300 PSP units

Education: M.Sc. In Corporate Law and Economics, Copenhagen Business School, and MBA, University of Melbourne
Previous experience: More than 25 years experience in corporate finance, venture capital, and the biotech industry, incl. Orphazyme A/S, MinervaX ApS, and Topotarget A/S.



Richard Jameson
Chief Commercial Officer
In Company since: 2016
Holdings: 29,193 shares and 6,082 PSP units

Education: B.Sc. in Applied Biological Sciences from University West of England
Previous experience: General Manager, UK & Nordics for Reckitt Benckiser (2010 – 2013) and Area Director Europe, Middle East and Africa for Indivior (2013 – 2016).



Fredrik Joabsson, PhD
Chief Business Dev. Officer
In Company since 2001
Holdings: 40,170 shares and 2,918 PSP units

Education: M.Sc. in Chemistry, PhD in Physical Chemistry, Lund University
Previous experience: More than 20 years of experience in pharmaceutical R&D, business development, alliance management and investor relations.



Markus Johnsson
Senior VP R&D
In Company since: 2003-2017, 2019-
Holdings: 16,000 shares and 2,918 PSP units

Education: Ph.D. in physical chemistry and M.Sc. in chemistry from Uppsala University.
Previous experience: More than 20 years of experience from pharmaceutical development and project management



Maria Lundqvist
Head of Global HR
In Company since 2021
Holdings: 2,918 PSP units

Education: B.Sc. in Business and Economics, Uppsala University.
Previous experience: More than 20 years of experience of leadership roles within Human Resources, including HR Director Nordics at Teva Pharmaceuticals and HR positions at Tetra Pak, Vestas and AstraZeneca.



Alberto M. Pedroncelli
Chief Medical Officer
In Company since 2023
Holdings: 1,000 shares, 20,000 employee options and 1,500 PSP units

Education: MD University of Milan. Ph. D. endocrinology post-graduate school University of London
Previous experience: Head of Clinical Development and Medical Affairs Recordati, Senior Leadership positions Novartis, clinician and research fellow Dept. Endocrinology, University Hospital Bergamo, Italy



Annette Mattsson
VP Regulatory Affairs
In Company since: 2017
Holdings: 2,004 shares and 2,918 PSP units

Education: Bachelor of Pharmacy, Uppsala University and Business Economics, Lund University
Previous experience: More than 25 years of experience within regulatory affairs, including European RA Director/Global RA Lead at AstraZeneca and Global RA Lead at LEO Pharma.



Agneta Svedberg
VP Clinical Dev.
In Company since: 2015
Holdings: 22,987 shares and 2,918 PSP units

Education: M.Sc. In Radiophysics and B.Sc. In Medicine from Lund University, Executive MBA from Executive Foundation Lund
Previous experience: More than 25 years of experience in drug development, incl. as COO at Zealand Pharma, CEO of Cantargia, Senior VP Clinical Development at Genmab.



Behshad Sheldon
President Camurus Inc.
In Company since 2024
Holdings: 1,000 shares, 2,000 employee options and 2,918 PSP units

Education: B.Sc. in Neuroscience from University of Rochester
Previous experience: More than 25 years of experience from the international pharma industry, including President & CEO of Braeburn Pharmaceuticals and senior positions within Smithkline Beecham, Bristol-Myers Squibb and Otsuka Pharmaceuticals.



Susanne Lagerlund
VP, Technical Operations
In Company since 2023
Holdings: 250 shares and 2,618 PSP units

Education: M. Sc. Chemical Engineering and studies Business Eonoics, Lund University
Previous experience: More than 30 years of experience from pharmaceutical industry, including Global Regulatory CMC Director at AstraZeneca, VP Regulatory Affairs at Cantargia, and Global Portfolio Lead at LEO Pharma.



Bo A. C. Tarras-Wahlberg
VP Legal & Group General Counsel
In Company since 2024
Holdings: 2,918 PSP units

Education: LLM from Lund University and studies at Queen Mary College
Previous experience: More than 20 years of experience as lawyer and from international senior legal positions, incl. as Assoc. General Counsel at Baxter, Gambro, legal private practice and as law clerk at District Court.